The Xativa Hub is an Australian patient access gateway and an information hub for GPs and specialists to find out more about current research and treatment products available in Australia.
Cannabis’ medicinal properties have been known for millennia. Cannabis was first thought to have originated from Central Asia and was used by many ancient societies. In fact, indications for therapeutic use of cannabis were mentioned in the texts of the Indian Hindus, Assyrians, Greeks and Romans. Cannabis was described to have helped alleviate and treat many health ailments, including pain, depression, inflammation, appetite loss and asthma related problems.
The Cannabis plant contains two of the most prominent cannabinoids; Cannabidiol (CBD) and Delta-9-Tetrahydrocannabinol (THC). Through the Endocannabinoid System in our body, CBD and THC interact to have various effects.
The endocannabinoid system (ECS) is a complex cell-signalling system found throughout our body. It consists of three key components, including:
Two key receptors:
CB1 - mainly found in central nervous system
CB2 - mainly found in peripheral nervous system
Endocannabinoids bind to either receptor & effects depend on where the receptor is located.
The endocannabinoid system plays a critical role in balancing many processes in our body, including immune response, appetite, sleep, et cetera.
Our innovative sublingual medicinal cannabis wafers are currently supplied in Australia through a special access scheme.
Our Xativa CBD wafers have been voted the Best CBD Edible (Sublingual) Product at the World CBD Awards 2022, and was previously voted the "CBD Product of the Year" in the Cannabis Industry Awards in Australia in 2020.
The awards celebrate the best-in-class in the CBD and Hemp industry for their standards, excellence, and achievements. Products nominated for the awards undergo a rigorous judging process employing lab report results, research panel reports, physical testing, application, and supporting documents as well as an aesthetics and safety report. The benchmarks are thoroughly examined by and independent panel of qualified and respected scientists, physicians, and professionals who are experts in the CBD or Hemp industry.
Medicinal cannabis is currently consumed in many different ways, most notably via ingestion of oral preparations such as tinctures, oils and capsules, and through vaporising and smoking.
Our sublingual medicinal cannabis wafers come in a discreet and convenient fixed dosage form and are the best approach for faster and more predictable absorption, hence improving outcomes.
Through advancements in scientific research, it is now known that different cannabinoids may be more effective for certain conditions. To meet the needs of every unique patient, we have created a line of products that contain CBD, THC and CBD and THC in varying dosage levels. If recommended by their physician, patients are able to start treatment with a low dose before titrating up to a more potent dose.
The Xativa Hub is an Australian patient access gateway and an information hub for GPs and specialists to find out more about current research and treatment products available in Australia.